2012-11-01T13:15:27-05:00 2011-12-31 521855942 TATE AND TRYON 2021 L STREET NW SUITE 400 WASHINGTON DC 20036 990 2011-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 PAUL AINES 5714831300 2012-11-01 1 DEBORAH G KOSNETT P00290720 2022932200 2011 2016-02-24 21:20:13Z ASCO ALLEN LICHTER MD 2318 MILL ROAD NO 800 ALEXANDRIA VA 22314 139032590 0 X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 18 17 303 1200 10576109 2108381 8931139 7731584 70399472 72435660 761935 2649887 -537553 327026 79554993 83144157 1766751 1923073 0 0 26424110 26305710 193150 520215 4735797 41452554 43619831 69836565 72368829 9718428 10775328 157835906 162402498 93957853 103704424 63878053 58698074 X ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY CARE.ASCO VISION STATEMENTS:-- ALL CANCER PATIENTS WILL HAVE LIFELONG ACCESS TO HIGH QUALITY, EFFECTIVE, AFFORDABLE AND COMPASSIONATE CARE.-- THE MOST ACCURATE CANCER INFORMATION WILL BE AVAILABLE SO THAT PATIENTS AND PHYSICIANS CAN MAKE INFORMED DECISIONS ABOUT CANCER PREVENTION AND TREATMENT.-- INFORMATION WE LEARN FROM EVERY PATIENT WILL BE USED TO ACCELERATE PROGRESS AGAINST CANCER.-- RESOURCES WILL EXIST TO ATTRACT THE BEST CLINICIANS AND INVESTIGATORS TO PROVIDE OPTIMAL PATIENT CARE AND TO CONDUCT TRANSFORMATIVE RESEARCH. --ASCO WILL BE RECOGNIZED AS THE MOST TRUSTED SOURCE OF CANCER INFORMATION WORLDWIDE. 0 0 28457856 1239672 44349572 EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS AND PROFESSIONAL DEVELOPMENT: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A WIDE VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF DIFFERENT FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCE KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE.THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM.ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2011 ACTIVITIES INCLUDE: APPROXIMATELY 32,000 PEOPLE ATTENDED THE 2011 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES, CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2011 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2011 ANNUAL MEETING FEATURED OVER 250 EDUCATIONAL AND SCIENTIFIC SESSIONS AND NEARLY 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. OVER 2,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY.-- IN 2011, ASCO WAS THE LEAD SPONSOR OF SEVERAL THEMATIC SYMPOSIA FOCUSING ON GENITOURINARY CANCERS, GASTROINTESTINAL CANCERS, BREAST CANCER, AND HEALTH INFORMATION TECHNOLOGY, COLLECTIVELY DRAWING OVER 6,000 ATTENDEES. THESE THEMATIC SYMPOSIA WERE OPEN TO THE GENERAL PUBLIC. -- IN 2011, ASCO SPONSORED OR CO-SPONSORED OVER 30 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN (AND) AROUND THE WORLD. THESE MEETINGS INCLUDE: -- ANNUAL MEETING -- GI SYMPOSIUM -- GU SYMPOSIUM -- BREAST CANCER SYMPOSIUM -- HEALTH INFORMATION TECHNOLOGY -- BEST OF ASCO SEATTLE -- BEST OF ASCO MIAMI -- ASCO/AACR METHODS WORKSHOPINTERNATIONAL AFFAIRS MEETINGS AND COURSES -- BEST OF ASCO INTERNATIONAL (19) -- JOINT SYMPOSIA (12) -- ADVANCED CANCER COURSES (5)ASCO PUBLISHES ASCO DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. 10970608 50000 23954819 EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES TWO EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JCO INCLUDES ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS, AND OTHER WORK THAT RELATE TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THEREBY INCREASING ITS USE INTERNATIONALLY.JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH, FEATURE ARTICLES, AND COLUMNS ON CLINICAL AND ADMINISTRATIVE MANAGEMENT FOR PRACTICING ONCOLOGISTS, WHICH ARE EDITED BY ONCOLOGISTS.IN 2011, THE JOURNAL OF CLINICAL ONCOLOGY HAD 24,100 ANNUAL SUBSCRIBERS. ADDITIONALLY, THE JCO IMPACT FACTOR INCREASED FOR A FIFTH CONSECUTIVE YEAR, AS REPORTED BY THOMSON REUTERS IN ITS 2010 JOURNAL CITATION REPORT. THE RISE IN THE IMPACT FACTOR OF NEARLY 50% SINCE 2005 IS A REFLECTION OF THE VALUE RESEARCHERS FIND IN JCO CONTENT. 7216907 219815 37230 CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RELATING TO CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE TO ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, EVIDENCE-BASED GUIDELINES AND TECHNOLOGY ASSESSMENTS, QUALITY ASSESSMENT/IMPROVEMENT, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS AND LEGAL ANALYSIS, EDUCATIONAL WORKSHOPS AND MATERIALS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY.CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE. IN 2011, ASCO'S ACTIVITIES INCLUDED EFFORTS IN THE FOLLOWING AREAS:ADVANCED CANCER- ASCO PUBLISHED A POSITION PAPER ON COMMUNICATION AND DECISION MAKING FOR PATIENTS WITH ADVANCED CANCER. THE PAPER OUTLINES THE GOALS FOR INDIVIDUALIZED CARE, BARRIERS THAT CURRENTLY LIMIT REALIZATION OF THIS VISION, AND POSSIBLE STRATEGIES TO OVERCOME THESE BARRIERS THAT CAN IMPROVE CARE CONSISTENT WITH THE WISHES OF PATIENTS AND EVIDENCE-BASED MEDICINE.CANCER CARE DISPARITIES- TO HELP ADDRESS SERIOUS RACIAL AND ECONOMIC DISPARITIES IN CANCER PREVENTION, DIAGNOSIS, AND TREATMENT IN THE UNITED STATES, ASCO PUBLISHED A POLICY STATEMENT OUTLINING SPECIFIC PROVISIONS OF 2010 PATIENT PROTECTION AND AFFORDABLE CARE ACT THAT HAVE THE POTENTIAL TO REDUCE THESE DISPARITIES. ASCO'S STATEMENT MAKES RECOMMENDATIONS TO ENSURE THAT SUCH PROVISIONS ARE CARRIED OUT EFFECTIVELY, AND URGES ADDITIONAL STEPS TO ADDRESS SYSTEMIC ISSUES INCLUDING INSURANCE REFORM, QUALITY OF CARE, PREVENTION, RESEARCH, AND DIVERSITY IN THE HEALTH CARE WORKFORCE.THE STATE/REGIONAL AFFILIATE PROGRAM- THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO ADDRESS ISSUES RELATING TO THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL.FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCH- ASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH. STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC).ORIGINAL DATA COLLECTION- ASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. IN 2011, ASCO COMPLETED THE STUDY OF COLLABORATIVE PRACTICE ARRANGEMENTS FUNDED BY SUSAN G. KOMEN FOR THE CURE(R). THE STUDY DETERMINED THAT COLLABORATIVE PRACTICE TEAMS OF ONCOLOGISTS AND NURSE PRACTITIONERS OR PHYSICIAN ASSISTANTS IMPROVE THE EFFICIENCY OF CANCER CARE AND CONTRIBUTE TO HIGH SATISFACTION RATES FOR PROVIDERS AND PATIENTS. 9569928 413586 4094039 QUALITY: THE ASCO QUALITY DEPARTMENT IS RESPONSIBLE FOR THE DEVELOPMENT OF EVIDENCE-BASED GUIDELINES, DEVELOPING AND VALIDATING QUALITY MEASURES IN ONCOLOGY, QUALITY IMPROVEMENT AND MEASUREMENT. THE DEPARTMENT IS ALSO TASKED WITH THE DEVELOPMENT OF THE FIRST RAPID LEARNING SYSTEM IN ONCOLOGY WHICH IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, DO RESEARCH, LEARN, AND INTERACT WITH THEIR PATIENTS. PROGRAMS INCLUDE:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI)- A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3)COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING HAWAII, ALASKA, GUAM, AND PUERTO RICO ARE ENROLLED IN THE PROGRAM.QOPI CERTIFICATION PROGRAM- THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE.THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A LIMITED LIABILITY COMPANY (LLC), THE INSTITUTE OF CLINICAL EXCELLENCE, LLC (ICE). (D/B/A QOPI CERTIFICATION PROGRAM) THE SOLE MEMBER AND MANAGER OF ICE IS ASCO. THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO PROMOTE HIGH QUALITY CANCER CARE, PROVIDE A TRUSTED SOLUTION TO ADDRESS EXTERNAL DEMAND FOR QUALITY ACTIVITIES, AND REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO DEMONSTRATION OF QUALITY.NEW GUIDELINES AND ONGOING UPDATES- ASCO NOW HAS 27 PUBLISHED PRACTICE GUIDELINES AND 3 PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. AN ADDITIONAL 4 GUIDELINES AND 1 PCO ARE IN DEVELOPMENT, ALONG WITH 8 UPDATES TO EXISTING GUIDELINES. IN ADDITION, ASCO HAS ENDORSED TWO GUIDELINES DEVELOPED BY OUTSIDE ORGANIZATIONS.MEMBER SERVICES: MEMBER SERVICES WORKS TO SUPPORT ASCO'S MORE THAN 30,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND E-MAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS.ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES. ASCOCONNECTION.ORG FEATURES BLOGS BY LEADERS IN THE FIELD, DISCUSSION FORUMS, COMMENT-ENABLED ARTICLES, AND OPPORTUNITIES TO CREATE GROUPS.COMMUNICATIONS AND PATIENT INFORMATION: ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER. IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT, CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR, BOOKLETS ON CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS.ADDITIONAL RESOURCES ARE AVAILABLE ON CANCER.NETFIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST.CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA.WHAT TO KNOW ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS.RESEARCH AND MEETINGS: INFORMATION ON ASCO'S CLINICAL CANCER ADVANCES REPORT, ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS. MULTIMEDIA: MEDICAL ILLUSTRATIONS, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING.EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH.CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT.ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS.CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. 9569928 413586 4094039 56215299 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 1 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1 407 0 1 303 1 1 1 0 0 0 0 0 0 0 0 0 X 18 17 0 0 1 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 VA NY X PAUL AINES CPA CFO 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 MICHAEL LINK MD 10-13 1.00 X X 10000 0 0 SANDRA SWAIN MD 08-12 1.00 X X 0 0 0 JAMES ABBRUZZESE MD 1.00 X 0 0 0 EDUARDO CAZAP MD 1.00 X 0 0 0 GARY COHEN MD 1.00 X 0 0 0 SUSAN COHN MD 1.00 X 500 0 0 DANIEL F HAYES MD 1.00 X 0 0 0 MARTIN MURPHY JR PHD DMEDSC 1.00 X 0 0 0 LORI PIERCE MD 1.00 X 0 0 0 CAROLYN RUNOWICZ MD 1.00 X 0 0 0 LYNN SCHUCHTER MD 1.00 X 2250 0 0 FRANCES SHEPHERD MD 1.00 X 500 0 0 GEORGE SLEDGE MD 08-11 1.00 X 0 0 0 EVERETT VOKES MD 1.00 X 1500 0 0 JULIE VOSE MD 1.00 X 500 0 0 ERIC WINER MD 1.00 X 1000 0 0 PETER YU MD 1.00 X 500 0 0 ROBIN ZON MD FACP 1.00 X 500 0 0 MONICA BERTAGNOLLI MD 1.00 X 0 0 0 BRUCE JOHNSON MD 1.00 X 0 0 0 ROBERT LANGDON MD 1.00 X 0 0 0 ALLEN LICHTER MD 37.50 X X 748894 0 20162 CLIFFORD HUDIS MD 09-12 1.00 X X 25750 0 0 PAUL AINES CPA 37.50 X 287362 0 32951 DINA MICHELS ESQ 37.50 X 468167 0 34067 NANCY DALY MSMPH 37.50 X 210524 0 23931 JEAN COLVARD 37.50 X 204814 0 18616 DEBORAH KAMIN RNPHD 37.50 X 285056 0 28788 BERNIE KHOO 37.50 X 330928 0 34884 CARA MOLINARI 37.50 X 178782 0 12251 THERESA VAN SCHAIK 37.50 X 179248 0 22225 SUZANNE BRACH 37.50 X 194974 0 23504 KRISTIN LUDWIG 37.50 X 221216 0 13690 KAY NOLL 37.50 X 191726 0 16958 DOUGLAS PYLE 37.50 X 180714 0 26013 ROBERT HAUSER PHARMD PHD 37.50 X 166642 0 4410 3892047 0 312450 56 0 1 0 THE MERZ GROUP 1570 MCDANIEL DR WEST CHESTER PA 19380 BRANDING 651939 POLSINELLI SHUGHART PC 1152 15TH STREET NW WASHINGTON DC 20005 LEGAL 628385 ASTUTE TECHNOLOGY 11718 BOWMEN GREEN DR RESTON VA 20190 VIDEO RECORDING 499353 BECKSTEIN PRODUCTION LLC 12415 ROUSSEAU TERRACE NORTH POTOMAC MD 20878 CREATIVE DEVELOPMENT 324996 MCDERMOTT WILL & EMERY LLP 28 STATE STREET BOSTON MA 02109 LEGAL 169592 10 7731584 7731584 EDUCATION MTGS & PROD 900099 24497991 24497991 PUBLICATIONS 511190 13025746 13025746 MEMBERSHIP 900099 10987041 10987041 ADVERTISING 541800 10929073 10929073 EXHIBITS 900099 9173631 9173631 3822178 3737157 85021 72435660 2029120 2029120 751 751 378423 378423 945869 1463854 -517985 -517985 -517985 55044595 54393878 30701 650717 -30701 620016 620016 MAILING LIST 511120 386588 386588 OTHER 900099 80000 80000 466588 83144157 61421566 10576109 3414898 1470901 1470901 452172 452172 4206430 2457008 1354870 394552 17143384 11457543 3916864 1768977 1394622 1078095 212527 104000 2140029 1701697 247216 191116 1421245 1057068 262283 101894 507138 369909 137229 115860 115860 148941 148941 520215 520215 479535 479535 10337950 9332324 837991 167635 335665 300556 35109 454066 307499 137235 9332 2135628 1247720 887908 4815933 3593801 1222132 2801507 2453269 340304 7934 7271388 6576231 695157 2435632 1768475 608208 58949 389208 179183 210025 UBI TAX 440664 1161755 -721091 PRINTING & PRODUCTION 6027583 6023949 3629 5 POSTAGE & SHIPPING 1861587 1841341 20246 DEVELOPMENT FEE TO CONQ 1400000 1400000 1661546 1235862 414496 11188 72368829 56215299 11417733 4735797 300 300 5337194 6579091 4349645 5459559 3940777 3712320 65850181 8275028 59126488 57575153 75988397 88475115 7274631 35506 1818474 565454 157835906 162402498 4913286 4141575 15358538 16505330 48050000 48050000 25636029 35007519 93957853 103704424 X 63878053 58698074 63878053 58698074 157835906 162402498 X 10775328 -15955307 X X 0 1 1 X 0 X 2928249 9732535 9749125 8931139 7731584 39072632 8421317 55457162 54860215 58117275 58890339 235746308 89689 257198 155397 235462 386588 1124334 11439255 65446895 64764737 67283876 67008511 275943274 3589400 11825034 11459125 10056139 7731584 44661282 0 3589400 11825034 11459125 10056139 7731584 44661282 231281992 700422 2234994 1248387 848971 3354163 8386937 1418830 1237990 1445377 2794100 1677713 8574010 2119252 3472984 2693764 3643071 5031876 16960947 661354 2444918 2303656 2884051 2832350 11126329 14219861 71364797 69762157 73810998 74872737 304030550 0.76070 0.73680 0.05580 0.05960 X SCHEDULE A, PART IV, SUPPLEMENTAL INFORMATION: CHANGE IN FISCAL YEAR REPORTING: ASCO'S 2007 REPORTED FIGURES REPRESENT THE FINANCIAL TRANSACTIONS FROM ASCO'S SHORT-YEAR PERIOD OF SEPTEMBER 1 - DECEMBER 31, 2007. THIS SHORT-YEAR REPRESENTS A TRANSITIONAL REPORTING PERIOD FOR ASCO FROM A FISCAL YEAR END OF AUGUST 31ST TO A CALENDAR FISCAL YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 148941 148941 66178350 66327291 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 181000 152632 148210 148941 630783 250000 250000 250000 250000 1000000 1500000 214 214 15916 15916 7342677 7342677 47946496 4188204 43758292 10561008 4086824 6474184 57575153 LIABILITY UNDER INTEREST RATE SWAP AGREEMENT 19057519 TAXABLE BOND PAYABLE 15950000 35007519 83144157 72368829 10775328 -5427154 -10528153 -15955307 -5179979 84608011 1463854 1463854 83144157 0 83144157 73832683 1463854 1463854 72368829 0 72368829 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. AT A MINIMUM, THE 2008 THROUGH 2011 TAX YEARS ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. PART XI, LINE 8 - OTHER ADJUSTMENTS: LOSS ON VALUE OF INTEREST RATE SWAP -10,528,153. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE TO PART VIII 1,463,854. PART XIII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE TO PART VIII 1,463,854. 1 NORTH AMERICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 3320 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 12647 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 40294 RUSSIA AND NEWLY INDEPENDENT STATES 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 25115 EUROPE 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 107371 SOUTH AMERICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 56264 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 38628 MIDDLE EAST & NORTH AFRICA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 24496 SOUTH ASIA 0 0 PROGRAM SERVICES OUTREACH AND INTERNATIONAL CANCER EDUCATIONAL PROGRAMS 43707 0 0 0 0 0 0 308135 43707 351842 EUROPE CONTRIBUTION TO SUPPORT PROGRAMS ON INTERNATIONAL CANCER CONTROL 85180 EUROPE CONTRIBUTION TO SUPPORT PROGRAMS ADDRESSING CANCER IN EUROPE 15150 0 2 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD NORTH AMERICA 1 1100 CHECK 2220 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH ASIA 7 7700 CHECK 32334 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD EAST ASIA AND THE PACIFIC 5 5500 CHECK 14364 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD RUSSIA AND NEWLY INDEPENDENTS STATES 2 2200 CHECK 6402 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD MIDDLE EAST & AFRICA 3 3300 CHECK 7897 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SOUTH AMERICA 3 3300 CHECK 9485 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD SUB-SAHARAN AFRICA 1 1100 CHECK 8827 IN-KIND TRAVEL SUPPORT FOR EDUCATION ON QUALITY CANCER CARE BOOK 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) - THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING IN THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS OF REVIEW USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, AND TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT AND A SUBMIT ONE-YEAR REPORTS. 1 GRAHAM PELTON CONSULTING 39 BEECHWOOD RD SUMMIT NJ 07901 FUNDRAISING CONSULTANT 0 0 520215 -520215 520215 -520215 VA NY EXPLANATION OF FUNDRAISING PAYMENTS SCHEDULE G, PART I, LINE 2B, COLUMN (V) PAYMENTS TO GRAHAM PELTON WERE FOR FUNDRAISING SERVICES FOR ASCO'S 501(C)(3) RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY TO DETERMINE FUNDRAISING BEST PRACTICES - NO REVENUE WAS RECEIVED. 1 HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW 310 WASHINGTON DC 20036 521485477 501(C)(3) 6000 CONTRIBUTION FRIENDS OF CANCER RESEARCH 3299 K ST NW WASHINGTON DC 20007 521983273 501(C)(3) 20000 CONTRIBUTION AMERICAN COLLEGE OF SURGEONS 633 NORTH ST CLAIR CHICAGO IL 60611 362192800 501(C)(3) 25000 CONTRIBUTION NATIONAL ACADEMY OF SCIENCES 2101 CONSTITUTION AVENUE NW WASHINGTON DC 20418 530196932 501(C)(3) 53000 CONTRIBUTION BROOKINGS INSTITUTION 1775 MASSACHUSETTS AVE WASHINGTON DC 20036 530196577 501(C)(3) 10000 CONTRIBUTION WASHINGTON HOSPITAL CENTER 110 IRVING ST NW WASHINGTON DC 20010 521272129 501(C)(3) 42652 CONTRIBUTION KOMEN NAT'L RACE FOR THE CURE 1911 N FORT MYER DR 112 ARLINGTON VA 22209 751835298 501(C)(3) 30000 CONTRIBUTION CONQUER CANCER FOUNDATION 2318 MILL ROAD 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 871450 CONTRIBUTION MEMORIAL SLOAN KETTERING CANCER CENTER PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 44274 CONTRIBUTION INDIANA UNIVERSITY 620 UNION DRIVE INDIANAPOLIS IN 46202 356001673 501(C)(3) 85231 CONTRIBUTION STANFORD UNIVERSITY 1000 WELCH ROAD 301 STANFORD CA 94301 941156365 501(C)(3) 143294 CONTRIBUTION PREVENT CANCER FOUNDATION 1600 DUKE ST 500 ALEXANDRIA VA 22314 521429544 501(C)(3) 45000 CONTRIBUTION CANCERCARE 275 7TH AVE NEW YORK NY 10001 131825919 501(C)(3) 5000 CONTRIBUTION BREAST CANCER RESEARCH FOUNDATION 654 MADISON AVE 1209 NEW YORK NY 10021 133727250 501(C)(3) 15000 CONTRIBUTION NATIONAL COALITION FOR CANCER SURVIVORSHIP 1010 WAYNE AVE 770 SILVER SPRING MD 20910 850357897 501(C)(3) 25000 CONTRIBUTION DUKE CANCER CENTER 2424 ERWIN RD SUITE 601 DURHAM NC 27705 560532129 501(C)(3) 50000 CONTRIBUTION 16 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: IN PRIOR YEARS, ASCO GRANTED SEVERAL SPECIAL AWARDS INTENDED TO RECOGNIZE AND ENCOURAGE INDIVIDUALS OR ORGANIZATIONS WHOSE COMMITMENT TO FURTHERING THE PROGRESS AGAINST CANCER HAS LED TO TREMENDOUS CONTRIBUTIONS TO THE FIELD OF CLINICAL ONCOLOGY, CANCER PATIENTS, AND ASCO. IN 2011, ASCO TRANSFERRED THESE AWARD PROGRAMS TO ITS RELATED 501(C)(3) ORGANIZATION, THE 'CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY.' X 1 1 X X X X X X 0 0 0 0 0 0 0 1 1 1 ALLEN LICHTER MD 666323 0 67571 0 15000 0 18375 0 1787 0 769056 0 0 0 PAUL AINES CPA 282362 0 5000 0 0 0 16442 0 16509 0 320313 0 0 0 DINA MICHELS ESQ 468167 0 0 0 0 0 18375 0 15692 0 502234 0 0 0 NANCY DALY MSMPH 199675 0 10849 0 0 0 11722 0 12209 0 234455 0 0 0 JEAN COLVARD 200814 0 4000 0 0 0 12346 0 6270 0 223430 0 0 0 DEBORAH KAMIN RNPHD 279056 0 6000 0 0 0 13096 0 15692 0 313844 0 0 0 BERNIE KHOO 327928 0 3000 0 0 0 18375 0 16509 0 365812 0 0 0 CARA MOLINARI 173782 0 5000 0 0 0 6092 0 6159 0 191033 0 0 0 THERESA VAN SCHAIK 174248 0 5000 0 0 0 10096 0 12129 0 201473 0 0 0 SUZANNE BRACH 190974 0 4000 0 0 0 11308 0 12196 0 218478 0 0 0 KRISTIN LUDWIG 216216 0 5000 0 0 0 12462 0 1228 0 234906 0 0 0 KAY NOLL 187726 0 4000 0 0 0 10731 0 6227 0 208684 0 0 0 DOUGLAS PYLE 176714 0 4000 0 0 0 10385 0 15628 0 206727 0 0 0 ROBERT HAUSER PHARMD PHD 136642 0 30000 0 0 0 0 0 4410 0 171052 0 0 0 PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED TO THE CEO, WHICH IS CONSIDERED PART OF THE CEO'S COMPENSATION AND ADDRESSED IN THE CEO'S WRITTEN EMPLOYMENT CONTRACT. THE HOUSING ALLOWANCE IS TREATED AS TAXABLE COMPENSATION. PART I, LINE 7 PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. PART I, LINE 8 CERTAIN AMOUNTS PAID OR ACCRUED TO THE CEO AND THE VP/GC WERE PURSUANT TO A CONTRACT THAT WAS SUBJECT TO THE INITIAL CONTRACT EXCEPTION DESCRIBED IN TREAS. REGS. SECTION 53.4958-4(A)(3). INDUSTRIAL DEVELOPMENT AUTHORITY CITY OF ALEXANDRIA 521381432 01530LAD2 2008-04-23 48050000 BUY/BLDOUT 5 FLS HQ BLDG 0 0 0 48050000 79362 47970638 2008 0 0 1 1 0 0 1 1 0 0.00000 0.08300 0.08300 1 0 1 1 DEPFA BANK 30.000000000000 0 0 0 0 0 X PART III, QUESTION 6 THE PERCENTAGE OF FINANCED PROPERTY USED IN A PRIVATE BUSINESS USE AS A RESULT OF UNRELATED BUSINESS ACTIVITY IS 8.3% FOR 2011. HOWEVER, THE AVERAGE ANNUAL PERCENTAGE OF PRIVATE BUSINESS USE SINCE THE BEGINNING OF THE MEASUREMENT PERIOD IS LESS THAN 1%. PART IV, QUESTION 3: ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH DEPFA BANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THESE INTEREST RATE SWAP AGREEMENTS QUALIFY AS A DERIVATIVE INSTRUMENT AND ARE USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2011, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH VOTING RIGHTS: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND 14 DIRECTORS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED BY VOTING MEMBERS OF ASCO AND HAVE THE SAME VOTING RIGHTS. THE CHIEF EXECUTIVE OFFICER (CEO) IS AN EX-OFFICIO, NON-VOTING MEMBER OF THE BOARD OF DIRECTORS. ADDITIONALLY, THE CHAIR OF THE BOARD OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX EXEMPT RELATED ORGANIZATION OF ASCO) IS AN EX-OFFICIO, NON-VOTING MEMBER OF THE BOARD OF DIRECTORS OF ASCO. DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. DURING THE REPORTING YEAR, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THEIR FINAL YEAR OF THEIR TERM. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 1 ONE VOTING MEMBER OF ASCO'S BOARD OF DIRECTORS DOES NOT MEET THE DEFINITIONAL TEST OF AN INDEPENDENT MEMBER OF ASCO'S GOVERNING BODY: CLIFFORD HUDIS, MD IS THE TREASURER OF ASCO AND A VOTING MEMBER OF ASCO'S BOARD OF DIRECTORS. HE WAS COMPENSATED BY ASCO FOR HIS WORK AS AN EDITOR TO JOURNAL OF CLINICAL ONCOLOGY. FORM 990, PART VI, SECTION A, LINE 4 IN 2011, VOTING ASCO MEMBERS APPROVED AMENDMENTS TO ASCO'S BYLAWS, WHICH INCLUDED: --ADDING A NEW STUDENT/NON-ONCOLOGY RESIDENT MEMBERSHIP CATEGORY. THESE MEMBERS ARE NOT ENTITLED TO HOLD OFFICE, VOTE, OR SERVE AS VOTING MEMBERS ON ASCO COMMITTEES; --CHANGING THE NAMES OF SOME MEMBERSHIP CATEGORIES; --REMOVING DETAILS FROM THE BYLAWS THAT COULD BE ADDRESSED IN OTHER POLICY DOCUMENTS (SUCH AS SPONSORSHIP OF MEMBERSHIP AND OF ABSTRACTS SUBMITTED TO ASCO MEETINGS AND REFERENCES TO SOME COMMITTEES) --ADDING THE CHAIR OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO'S RELATED, NONPROFIT, 501(C)(3) TAX EXEMPT ORGANIZATION) AS AN EX OFFICIO, NON-VOTING MEMBER OF THE ASCO BOARD; --PROVIDING A PROCESS TO ADDRESS WHEN AN ASCO BOARD DIRECTOR CHANGES HIS/HER "CLASS" DURING HIS/HER TERM; --EXTENDING THE TERM OF THE DESIGNATED COMMUNITY ONCOLOGIST ON THE NOMINATING COMMITTEE FROM 1 TO 3 YEARS TO BE ON PAR WITH OTHER NOMINATING COMMITTEE MEMBERS; --HAVING MEMBERS ELECT THE DESIGNATED COMMUNITY ONCOLOGIST ON THE NOMINATING COMMITTEE; --CLARIFYING THAT BOTH THE BOARD AND MEMBERS MUST APPROVE BYLAWS AMENDMENTS; --USING THE REQUIRED MEMBER QUORUM NUMBER (100) AS THE NUMBER OF MEMBERS NEEDED TO PROPOSE BYLAWS AMENDMENTS; AND --MAKING VARIOUS NOTICE REQUIREMENTS CONSISTENT WITH EACH OTHER. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE CATEGORIES OF MEMBERSHIP AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR ACTIVE MEMBER STATUS. OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G., EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER ARE ELIGIBLE FOR ACTIVE MEMBER STATUS. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, SERVE ON ALL COMMITTEES OF ASCO, AND VOTE AND HOLD OFFICE IN ASCO. 2. INTERNATIONAL CORRESPONDING MEMBERS. 2.A. INTERNATIONAL CORRESPONDING MEMBERS ARE EXPERIENCED PHYSICIANS WHO ARE ELIGIBLE TO BE FULL MEMBERS, BUT WHO RESIDE IN A DEVELOPING NATION OR A NATION WITH A LOW PER-CAPITA INCOME, AS DEFINED BY THE BOARD OF DIRECTORS FROM TIME TO TIME. 2.B. RIGHTS OF INTERNATIONAL CORRESPONDING MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. INTERNATIONAL CORRESPONDING MEMBERS MAY NOT SERVE ON COMMITTEES OF ASCO, AND MAY NOT VOTE OR HOLD OFFICE IN ASCO. 3. ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS. 3.A. ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS ARE OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G., EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANK WHO ARE NOT ELIGIBLE TO BE AN FULL MEMBER AND WHO HAVE A PREDOMINANT INTEREST IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 3.B. RIGHTS OF ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS AND TO SERVE ON ALL COMMITTEES OF ASCO. ACTIVE-ALLIED MEMBERS MAY NOT VOTE OR HOLD OFFICE IN ASCO. 4. AFFILIATED HEALTH PROFESSIONAL MEMBERS. 4.A. AFFILIATED HEALTH PROFESSIONAL MEMBERS ARE AFFILIATED HEALTH PROFESSIONALS IN ONCOLOGY, INCLUDING ONCOLOGY NURSES, PHYSICIAN ASSISTANTS, AND OTHER HEALTH SPECIALISTS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO THE CARE AND TREATMENT OF PATIENTS WITH NEOPLASTIC DISEASES. MEMBERSHIP IS LIMITED TO THOSE PERSONNEL WHO FUNCTION AS INTEGRAL MEMBERS OF A TEAM OF ONCOLOGISTS RESPONSIBLE FOR THE CARE OF SUCH PATIENTS OR WHO ENGAGE IN THE CONDUCT OF CLINICAL TRIALS. ELECTION TO MEMBERSHIP IS BASED ON EXPERIENCE IN AND CONTRIBUTIONS TO THE FIELD OF ONCOLOGY. ADDITIONALLY, AFFILIATED HEALTH PROFESSIONAL MEMBERS STATUS INCLUDES INDIVIDUALS WHO HOLD LEADERSHIP POSITIONS OR HAVE TAKEN A DISTINGUISHED LEADERSHIP ROLE IN A NATIONALLY OR INTERNATIONALLY RECOGNIZED NOT-FOR-PROFIT, TAX-EXEMPT ORGANIZATION DEDICATED TO CANCER PATIENT ADVOCACY OR SURVIVORSHIP. 4.B. RIGHTS OF AFFILIATED HEALTH PROFESSIONAL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS AND SERVE ON ALL COMMITTEES OF ASCO. AFFILIATED HEALTH PROFESSIONAL MEMBERS MAY NOT VOTE OR HOLD OFFICE IN ASCO. 5. EMERITUS MEMBERS. 5.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 65, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 5.B. RIGHTS OF EMERITUS MEMBERS INCLUDE BEING EXEMPT FROM MEMBERSHIP DUES. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN ALL RIGHTS AND PRIVILEGES OF FULL MEMBER STATUS, EXCEPT THE HOLDING OF OFFICE. EMERITUS MEMBERS WHO WERE PREVIOUSLY ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBERS RETAIN ALL THE RIGHTS AND PRIVILEGES OF ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING OR AFFILIATED HEALTH PROFESSIONAL MEMBER STATUS RESPECTIVELY. 6. HONORARY MEMBERS. 6.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 6.B. RIGHTS OF HONORARY MEMBERS INCLUDE HAVING ALL PRIVILEGES OF FULL MEMBERS, EXCEPT THEY MAY NOT HOLD OFFICE AND ARE EXEMPT FROM PAYING MEMBERSHIP DUES. 7. MEMBER IN TRAINING MEMBERS. 7.A. MEMBER IN TRAINING MEMBERS ARE HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL WHO ARE PARTICIPATING IN A SUBSPECIALTY TRAINING PROGRAM IN ONCOLOGY OR ANOTHER FIELD THAT WOULD LEAD TO ELIGIBILITY FOR FULL OR ALLIED PHYSICIAN/DOCTORAL SCIENTIST MEMBERSHIP. 7.B. RIGHTS OF MEMBER IN TRAINING MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. MEMBER IN TRAINING MEMBERS MAY NOT HOLD OFFICE OR VOTE, EXCEPT THAT THEY MAY SERVE AS VOTING MEMBERS OF COMMITTEES OF ASCO. 8. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS. 8.A. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS ARE MEDICAL RESIDENTS, MEDICAL STUDENTS, GRADUATE STUDENTS, AND UNDERGRADUATE STUDENTS WHO ARE ENROLLED IN A BIOMEDICAL NURSING OR ALLIED HEALTH PROGRAM, AND WHO HAVE A PREDOMINANT INTEREST IN THE BIOLOGY, DIAGNOSIS, PREVENTION, OR TREATMENT OF HUMAN CANCER. 8.B. RIGHTS OF STUDENT/NON-ONCOLOGY RESIDENT MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS. STUDENT/NON-ONCOLOGY RESIDENT MEMBERS ARE NOT ELIGIBLE TO VOTE OR HOLD OFFICE OR TO SERVE AS VOTING MEMBERS OF COMMITTEES OF ASCO. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS: THE PRESIDENT, PRESIDENT-ELECT, PAST-PRESIDENT, TREASURER, AND 14 DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF) (FORMERLY KNOWN AS THE ASCO CANCER FOUNDATION); THE PRESIDENT OF INSTITUTE OF CLINICAL EXCELLENCE, LLC (D/B/A QOPI CERTIFICATION PROGRAM); AND THE PRESIDENT OF ASCO LEASING LLC. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. IN 2010, THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT HAD COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE INDEPENDENT COMPENSATION CONSULTANT'S 2010 OPINION ON THE CEO'S COMPENSATION CONTEMPLATED MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. IN 2011, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND REVIEWED AGAIN THE 2010 OPINION OF ITS INDEPENDENT COMPENSATION CONSULTANT THAT THE CEO'S COMPENSATION WAS REASONABLE, INCLUDING THE CONSULTANT'S OPINION ON THE MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. COMPENSATION OF CERTAIN OFFICERS AND KEY EMPLOYEES OF ASCO VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. IN 2010, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT HAD COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. IN 2011, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND THE INDEPENDENT COMPENSATION CONSULTANT, WHICH UPDATED ITS 2010 OPINION AND FOUND AGAIN THAT THE VP/GC'S PROPOSED COMPENSATION, WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. CHIEF FINANCIAL OFFICER (CFO). THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. IN 2010, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE INDEPENDENT COMPENSATION CONSULTANT'S 2010 OPINION ON THE COMPENSATION OF THE CFO CONTEMPLATED MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. IN 2011, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND REVIEWED AGAIN THE 2010 OPINION OF ITS INDEPENDENT COMPENSATION CONSULTANT THAT THE CFO'S COMPENSATION WAS REASONABLE, INCLUDING THE CONSULTANT'S OPINION ON THE MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF) (FORMERLY KNOWN AS THE ASCO CANCER FOUNDATION). THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. IN 2010, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE. THE INDEPENDENT COMPENSATION CONSULTANT'S 2010 OPINION ON THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF CONTEMPLATED MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. . IN 2011, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND REVIEWED AGAIN THE 2010 OPINION OF ITS INDEPENDENT COMPENSATION CONSULTANT THAT THE EXECUTIVE DIRECTOR OF CCF'S COMPENSATION WAS REASONABLE, INCLUDING THE CONSULTANT'S OPINION ON THE MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY. THE BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. IN 2010, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE INDEPENDENT COMPENSATION CONSULTANT'S 2010 OPINION ON THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY CONTEMPLATED MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. IN 2011, THE BOARD COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND REVIEWED AGAIN THE 2010 OPINION OF ITS INDEPENDENT COMPENSATION CONSULTANT THAT THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY'S COMPENSATION WAS REASONABLE, INCLUDING THE CONSULTANT'S OPINION ON THE MARKET-BASED COMPENSATION INCREASES IN YEARS GOING FORWARD. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, WAS PUBLISHED IN THE JANUARY 20, 2006 EDITION OF JOURNAL OF CLINICAL ONCOLOGY (THE EDITION IS AVAILABLE TO THE PUBLIC FOR FREE), AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION A, LINE 7B: NO DECISIONS OF THE GOVERNING BODY ARE SUBJECT TO APPROVAL BY MEMBERS, STOCKHOLDERS, OR OTHER PERSONS. HOWEVER, THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 10B: ALTHOUGH ASCO HAS STATE AND REGIONAL AFFILIATES THROUGH ITS STATE AND REGIONAL AFFILIATE PROGRAM, ASCO DOES NOT HAVE THE LEGAL AUTHORITY TO EXERCISE SUPERVISION AND CONTROL OVER THEM AND EACH AFFILIATE IS A SEPARATELY INCORPORATED LEGAL ENTITY THAT IS RESPONSIBLE FOR ITS OWN FISCAL MANAGEMENT. AFFILIATES MAY NOT ACT ON BEHALF OF ASCO AND ARE PROHIBITED FROM ANY ACTION THAT MIGHT IMPLY AN AGENCY RELATIONSHIP. AFFILIATES MAY NOT BIND ASCO TO ANY CONTRACT WITH A THIRD PARTY. ASCO'S STATE AND REGIONAL AFFILIATE PROGRAM IS DESIGNED TO ASSIST STATE AND REGIONAL SOCIETIES IN ADDRESSING THE PRACTICAL ISSUES FACING PHYSICIANS WHO CARE FOR PEOPLE WITH CANCER AND TO FACILITATE AND ENCOURAGE INVOLVEMENT IN ASCO'S PUBLIC POLICY INITIATIVES. EACH AFFILIATE HAS A VOTING REPRESENTATIVE ON THE ASCO CLINICAL PRACTICE COMMITTEE (CPC), WHICH IS INTENDED TO ADDRESS THE PRACTICE OF ONCOLOGY, WITH A PARTICULAR FOCUS ON REIMBURSEMENT FOR, ACCESS TO, AND QUALITY OF MEDICAL ONCOLOGY SERVICES. THROUGH PARTICIPATION IN THE CPC, AFFILIATES HAVE A ROLE IN THE DEVELOPMENT OF PUBLIC POLICY POSITIONS AT THE NATIONAL LEVEL AND ALSO RECEIVES INPUT REGARDING STATE AND REGIONAL ISSUES AFFECTING ONCOLOGY. STATE AND REGIONAL SOCIETIES INTERESTED IN BEING AFFILIATES MUST SUBMIT AN APPLICATION TO ASCO THAT, AMONG OTHER THINGS, REQUIRES THEM TO DEMONSTRATE THAT THEY ARE VALIDLY INCORPORATED UNDER STATE LAW, HAVE IN PLACE GOVERNANCE PRACTICES AND PROCEDURES (BYLAWS, OFFICERS, DIRECTORS, ELECTIONS, MEETINGS, AND RESPONSIBLE FISCAL MANAGEMENT), AND HAVE PHYSICIAN MEMBERSHIP REQUIREMENTS THAT ARE CONSISTENT WITH ASCO'S STANDARDS. ASCO PROVIDES STATE AFFILIATES WITH A VARIETY OF ASSISTANCE, INCLUDING ASCO POLICY ANALYSES, ACCESS TO ASCO STAFF ON MATTERS OF INTEREST TO STATE AFFILIATES, AND ASSISTANCE WITH MEDIA AND OUTREACH. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -5,427,154. LOSS ON VALUE OF INTEREST RATE SWAP -10,528,153. TOTAL TO FORM 990, PART XI, LINE 5: -15,955,307. FORM 990, PART XII, LINE 2C COMMITTEE OVERSIGHT OF THE AUDIT--ASCO HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT AUDIT FIRM. THIS PROCESS HAS NOT CHANGED FROM THE PREVIOUS YEAR. INSTITUTE OF CLINICAL EXCELLENCE LLC 2318 MILL ROAD ALEXANDRIA VA 22314 271629211 QOPI CERTIFICATION PROGAM VA 85022 213980 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ASCO LEASING LLC 2318 MILL ROAD ALEXANDRIA VA 22314 273378225 RENTAL OF 5TH FLOOR VA 946187 190030 AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQUER CANCER FOUNDATION OF ASCO (CCF) 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 DEDICATED TO CONQUERING CANCER WORLDWIDE BY FUNDING RESEARCH VA 501 (C)(3) 509 (A)(1) 1 1 1 1 0 1 0 0 0 1 0 0 1 0 1 1 1 0 0 CCF A 231180 FMV CCF B 871450 FMV CCF C 7731584 FMV CCF E 64000000 FMV CCF I 231180 FMV CCF L 4676846 FMV CCF N 2560538 FMV CCF O 2327368 V CCF P 5425123 FMV